Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
Farmers Insurance
US Army

Generated: December 15, 2017

DrugPatentWatch Database Preview


« Back to Dashboard

When do Lamivudine patents expire, and what generic alternatives are available?

Lamivudine is a drug marketed by Aurobindo Pharma Ltd, Silarx Pharms Inc, Apotex, Apotex Inc, Appco Pharma Llc, Cipla Ltd, Eci Pharms Llc, Hetero Labs Ltd V, Lupin Ltd, Mylan Pharms Inc, Hetero Labs Ltd Iii, Pharmacare, Strides Pharma, and Teva Pharms. and is included in twenty-three NDAs.

The generic ingredient in LAMIVUDINE is lamivudine; zidovudine. There are twenty-eight drug master file entries for this compound. Twenty-four suppliers are listed for this compound. There are fifty tentative approvals for this compound. Additional details are available on the lamivudine; zidovudine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms IncLAMIVUDINE AND ZIDOVUDINElamivudine; zidovudineTABLET;ORAL204005-001Aug 28, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
PharmacareLAMIVUDINE AND ZIDOVUDINElamivudine; zidovudineTABLET;ORAL022018-001Mar 17, 2017BXRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdLAMIVUDINElamivudineSOLUTION;ORAL077695-001Nov 21, 2016AARXNoNo► Subscribe► Subscribe► Subscribe
Lupin LtdLAMIVUDINElamivudineTABLET;ORAL205217-001Dec 18, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdLAMIVUDINE AND ZIDOVUDINElamivudine; zidovudineTABLET;ORAL202418-001May 15, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Appco Pharma LlcLAMIVUDINElamivudineTABLET;ORAL206974-002Nov 21, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
ApotexLAMIVUDINElamivudineTABLET;ORAL091606-002Dec 2, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Cipla LtdLAMIVUDINElamivudineTABLET;ORAL077221-001Mar 3, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms IncLAMIVUDINElamivudineTABLET;ORAL204002-001Dec 31, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma LtdLAMIVUDINElamivudineTABLET;ORAL077464-001Nov 21, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Express Scripts
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: